Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-29 | Dr. Engelsen received his M.Sc. in nuclear chemistry and his M.D. from the University of Oslo and is a Certified European Financial Analyst (C.E.F.A.). |
| 2014-04-17 | Dr. Engelsen holds a Master of Science degree in nuclear chemistry and a Doctor of Medicine degree from the University of Oslo. |
| 2015-04-15 | Dr. Engelsen holds a Master of Science degree in nuclear chemistry and a Doctor of Medicine degree from the University of Oslo and is a Certified European Financial Analyst. The Board believes that Dr. Engelsen's finance and management experience in biopharmaceutical companies enables him to provide operating insights. |
| 2016-04-13 | Dr. Engelsen holds a Master of Science degree in nuclear chemistry and a Doctor of Medicine degree from the University of Oslo and is a Certified European Financial Analyst. |
| 2017-04-07 | Dr. Engelsen has more than 20 years of experience in the pharmaceutical industry, including his experience as a financial analyst and as an investor in biopharmaceutical companies. |
| 2018-04-05 | Dr. Engelsen's education includes M.S. in nuclear chemistry and M.D., and he has finance and management experience as well as public company board experience. |
| 2019-04-04 | Education and Certifications: University of Oslo - M.S., nuclear chemistry; University of Oslo - M.D.; Norwegian School of Economics - Certified European Financial Analyst |
| 2020-03-31 | Education and Certifications: University of Oslo - M.S., nuclear chemistry; University of Oslo - M.D.; Norwegian School of Economics - Certified European Financial Analyst |
| 2021-04-01 | Education: University of Oslo- M.S., nuclear chemistry; University of Oslo - M.D.; Norwegian School of Economics- Certified European Financial Analyst |
| 2022-04-01 | Education and Certifications: University of Oslo - M.S., nuclear chemistry; University of Oslo - M.D.; Norwegian School of Economics- Certified European Financial Analyst |
Data sourced from SEC filings. Last updated: 2026-02-03